As healthcare and life sciences technologies evolve, pharmaceutical companies are increasingly turning to artificial intelligence (AI) and machine learning solutions to accelerate drug development, increase efficiency, and reduce costs. Using generative AI to support clinical trial planning offers a range of benefits for pharma companies looking to maximize the impact of their therapies.

From trial site feasibility to patient populations and data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. In this Perspectives edition, we explore how AI is disrupting the clinical trial landscape.